Table 2 Treatment characteristics
From: First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
Patient no. | Sonication target and side | Final temperature (°C) | Global symptom relief 3 months (%) | Pre-FUS UPDRS I/II/III/IV (max. 16/52/56/23, total 147) | 3 months post-FUS UPDRS I/II/III/IV (max. 16/52/56/23, total 147) | Pre-FUS MMST (max. 30) | 3 months post-FUS MMST (max. 30) | Pre-FUS HADS (max. 42) | 3 months post-FUS HADS (max. 42) | |
|---|---|---|---|---|---|---|---|---|---|---|
Group 1 | 1 | PTT right | 52 | 0 | 0/2/3/6 | 2/11/5/7 | 29 | 30 | 17 | 20 |
Total 11 | Total 25 | |||||||||
2 | PTT right | 52 | 30 | 0/14/17/3 | 0/10/17/2 | 30 | 30 | 9 | 4 | |
Total 34 | Total 29 | |||||||||
3 | PTT right | 57 | 40 | 0/18/29/4 | 1/20/24/2 | 29 | 29 | 12 | 18 | |
Total 51 | Total 47 | |||||||||
4 | PTT right | 59 | 20 | 0/18/26/5 | 0/12/20/1 | 27 | 27 | 13 | 9 | |
Total 49 | Total 33 | |||||||||
Group 2 | 5 | PTT right | 59 | 50 | 0/5/18/5 | 0/1/7/0 | 30 | 30 | 5 | 9 |
Total 28 | Total 8 | |||||||||
6 | PTT left | 57 | 55 | 1/10/15/5 | 0/6/6/0 | 29 | 30 | 20 | 19 | |
Total 31 | Total 12 | |||||||||
7 | PTT left | 57 | 80 | 4/21/20/6 | 1/12/2/4 | 30 | 30 | 13 | 14 | |
Total 51 | Total 19 | |||||||||
8 | PTT right | 58 | 5 | 0/10/22/5 | 0/9/15/0 | 29 | 30 | 11 | 9 | |
Total 37 | Total 24 | |||||||||
9 | PTT left | 57 | 50 | 4/17/19/10 | 1/5/2/4 | 30 | 29 | 34 | 26 | |
Total 50 | Total 12 | |||||||||
10 | PTT right | 56 | 50 | 3/9/20/7 | 3/6/4/0 | 29 | 30 | 14 | 18 | |
Total 39 | Total 13 | |||||||||
11 | PTT right | 56 | 80 | 0/19/29/4 | 2/9/13/0 | 30 | 29 | 12 | 3 | |
Total 53 | Total 24 | |||||||||
12 | PTT right | 56 | 70 | 0/5/14/6 | 1/3/8/0 | 29 | 30 | 9 | 10 | |
Total 25 | Total 12 | |||||||||
13 | PTT left | 54 | 70 | 3/22/11/8 | 3/4/9/0 | 26 | 28 | 14 | 10 | |
Total 44 | Total 16 | |||||||||
Mean | - | 56.2 | - | - | - | 29 | 29.4 | 14.1 | 13 |